Production (Stage)
NurExone Biologic Inc.
NRXBF
$0.5318
$0.01011.94%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.00% | 8.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.56% | 15.49% | |||
| Operating Income | -14.56% | -15.49% | |||
| Income Before Tax | -8.54% | -23.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.54% | -23.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.54% | -23.68% | |||
| EBIT | -14.56% | -15.49% | |||
| EBITDA | -12.57% | -16.18% | |||
| EPS Basic | -5.07% | -10.15% | |||
| Normalized Basic EPS | -4.41% | -10.57% | |||
| EPS Diluted | -5.07% | -10.15% | |||
| Normalized Diluted EPS | -4.41% | -10.57% | |||
| Average Basic Shares Outstanding | 3.55% | 11.89% | |||
| Average Diluted Shares Outstanding | 3.55% | 11.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||